We read with a great deal of interest the recently published meta-analysis of Maharaj and Metaxa [1] describ ing the eff ects of levosimendan on mortality after coronary revascularization. Th e authors concluded that levosimendan is able to reduce mortality in patients undergoing myocardial revascularization. Th eir conclu sion, however, is unreliable and misleading for several reasons.
similar with respect to population, outcome and intervention. ' Th e article of Moharaj and Metaxa does not follow these simple principles. We believe it is not correct to include in the same analysis studies where levosimendan is used for the treatment of postoperative cardiogenic shock and studies where it is used as ischemic preconditioning before cardiopulmonary bypass [3, 4] . For example, the study of Tritapepe and colleagues [5] included in this meta-analysis describes the eff ects of a single low dose (24 mcg/kg) of levosimendan infused before cardiopulmonary bypass in patients under going surgical myocardial revascularization only for the assess ment of the possible preconditioning eff ect of the drug.
Although we believe that levosimendan is an eff ective drug for the treatment of cardiogenic shock, we also believe this meta-analysis does not provide enough evidence that levosimendan can decrease mortality after myocardial revascularization.
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Can a meta-analysis that mixes apples with oranges be used to demonstrate that levosimendan reduces mortality after coronary revascularization? 
L E T T E R Authors' response

Ritesh Maharaj and Victoria Metaxa
We would like to thank Dr Meco and colleagues for their interest in our recently published meta-analysis [1] . Th e main goal of meta-analyses is to obtain a summary estimate across data sets and is substantially diff erent to the aims of an individual trial [6, 7] . Accounting for trial level diff erences remains a signifi cant analytical challenge when pooling results, and we report how these diff erences may infl uence conclusions [8] . In our report we off er a qualitative assessment of the combinability or clinical heterogeneity by way of the study descriptors [1] . A small amount of between-trial heterogeneity can be accounted for by using the random eff ects model as opposed to the fi xed eff ects model. In our report the eff ect of levosimendan versus control using the random eff ects model remained consistent (odds ratio 0.43 (95% confi dence interval 0.21 to 0.89)).
Subgroup meta-analysis attempts to examine the eff ects of potential confounding, though we appreciate that such analyses should be interpreted with some consideration. We have conducted subgroup analyses comparing levosimendan in the elective versus emergent setting, as well as comparisons between levosimendan with other vasoactive agents and placebo. Th e fi ndings of these analyses are explained in the manuscript and are aimed at improving the clinical relevance of the conclusions drawn. Th ese methods aim to address the obvious heterogeneity that does exist and show a consistent clinical and biological signal in favor of levosimendan compared with control. A meta-analysis published ahead of print evaluating the role of levosimendan in mortality reduction and hospitalization included 45 studies that ranged from cardiology to sepsis and vascular and cardiac surgery settings [9] . Subgroup analysis of patients receiving a bolus, no bolus and dose >0.1 mcg/kg/minute all showed statistical signifi cance in favor of levosimendan. 
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